WO2015027730A1 - 显著升高血清高密度脂蛋白浓度的中药复合组合物和制备方法 - Google Patents

显著升高血清高密度脂蛋白浓度的中药复合组合物和制备方法 Download PDF

Info

Publication number
WO2015027730A1
WO2015027730A1 PCT/CN2014/079771 CN2014079771W WO2015027730A1 WO 2015027730 A1 WO2015027730 A1 WO 2015027730A1 CN 2014079771 W CN2014079771 W CN 2014079771W WO 2015027730 A1 WO2015027730 A1 WO 2015027730A1
Authority
WO
WIPO (PCT)
Prior art keywords
beef
chinese medicine
traditional chinese
powder
jisheng
Prior art date
Application number
PCT/CN2014/079771
Other languages
English (en)
French (fr)
Inventor
高庄存
高翔宇
Original Assignee
Gao Zhuangcun
Gao Xiangyu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gao Zhuangcun, Gao Xiangyu filed Critical Gao Zhuangcun
Priority to JP2016537097A priority Critical patent/JP6273017B2/ja
Priority to US14/771,505 priority patent/US9861664B2/en
Publication of WO2015027730A1 publication Critical patent/WO2015027730A1/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/34Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/32Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/35Fat tissue; Adipocytes; Stromal cells; Connective tissues
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/36Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/23Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/23Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/236Ligusticum (licorice-root)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/28Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/285Aucklandia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/72Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
    • A61K36/725Ziziphus, e.g. jujube
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/73Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A61K36/734Crataegus (hawthorn)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2095Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

  • the present invention relates to the field of prevention and treatment of heart and cerebrovascular diseases caused by atherosclerotic arch, with sputum and a significantly elevated serum High-density lipoprotein (HD concentration of traditional Chinese medicine compound prescription).
  • High density lipoprotein is mainly composed of liver and small intestine, and the smallest serum lipoprotein.
  • Dr. Miller of the United States first discovered the anti-atherosclerosis factor HDL, which revealed that coronary heart disease is not always caused by hyperlipidemia.
  • the decrease of HDL level may also be an important or even key for coronary heart disease.
  • the cause of sexual onset is mainly composed of liver and small intestine, and the smallest serum lipoprotein.
  • HDL high-density lipoprotein
  • HDL has a clear anti-atherosclerotic effect, which can "absorb” cholesterol from the atherosclerotic blood vessel wall and transport it to the liver for elimination.
  • Arterial angiography also confirmed a significant negative correlation between HDL content and arterial lumen stenosis, so HDL has the reputation of "vascular scavenger”.
  • the international medical community clearly understands J ⁇ "Who can significantly increase HDL, who solves the problem of coronary heart disease and even cardio-cerebral vascular disease, who can theoretically extend human silk for decades.
  • the object of the present invention is to provide a traditional Chinese medicine compound composition which significantly raises serum HDL, and to make up for the deficiencies of the prior art, so as to change the current state of clinical use of a traditional Chinese medicine which does not have an ideal serum HDL.
  • the traditional Chinese medicine compounding group of the invention is composed of the following two aspects: “Tune the middle piece” and “Jisheng San”.
  • the middle slice of the present invention is composed of the following drugs: Beishan, Muxiang, Beisha, and Chuanxiong, wherein the weight percentage of each component is: Beishan ⁇ 30 Q / M0%, woody 10% - 30%, Northern sand ginseng 103 ⁇ 4 ⁇ _30%, Chuanxiong 10% - 30%.
  • the percentage of each component of the middle-adjusting tablet of the present invention may also be: Beishan ⁇ 353 ⁇ 4 ⁇ " 45%, wood incense 15% - 25%, Northern sand ginseng 15% - 25%, j 11 ⁇ 15% - 25%
  • each component of the middle plate is: 40% of the northern hawthorn, 20% of the woody, 18% of the northern sand ginseng, and 22% of the Chuanxiong.
  • the main component of the middle tune is woody, medicinal, bitter, warm, Adjust the lead stagnation, spleen and digestion, the role of iM.
  • the drug is the drug.
  • Beishan Mountain Another important ingredient in the middle of the film is Beishan Mountain, which is medicinal acid, sweet, and lukewarm. It has the function of digestion and digestion, promoting blood circulation and removing blood stasis. Studies have shown that B. hawthorn can reduce blood lipids, improve blood circulation, prevent surface ion transmission, help stabilize myocardial, antihypertensive, and anti-atherosclerosis. In the middle of the film is a drug.
  • the four-flavor medicine in the middle of the film of the invention has the functions of nourishing the qi, invigorating the spleen and appetizing, correcting the deficiency of the spleen and stomach, restoring the normal physiological function of the spleen and stomach, and also having the functions of nourishing yin, promoting blood circulation and removing blood stasis.
  • the main focus of this disease is to start from the conditioning of the spleen and stomach function, the amino acid that is essential for the synthesis of LDL, the obstacles in the process of digestion, absorption and transformation of the human body as a therapeutic target, first restore the human body environment to synthesize the ideal HDL 7JC flat
  • the physiological basis has created a cake for the application of Jishengsan and its full effect, which is the key to significantly increase serum HDL concentration.
  • the preparation method of the middle film is a traditional Chinese medicine pharmaceutical process. 7 fried, m, made into tablets; can also be made into 1", pills, capsules.
  • the Jishengsan of the present invention is composed of the following drugs: beef, beef tendon, pig skin, jujube meat, wherein the weight percentage of each component is: beef 403 ⁇ 4 ⁇ "60%, beef tendon 15°/( ⁇ -35%, pig skin 15 ° / ( ⁇ - 35%, jujube meat 0. 5% - 2. 5%
  • the percentage of the components of the Jisheng San of the present invention may also be: beef 45 ° / ⁇ 5%, Beef tendon 20% - 30% pig skin 20% - 30%, jujube meat I 0 / 2%
  • each component of Jishengsan is: beef 50%, beef tendon 24%, pig skin 25%, jujube meat
  • Jishengsan the main ingredient in Jishengsan is beef, which is sweet, warm and non-toxic, and has the effect of protecting the qi and stomach. Rich in beef protein, it is the main source of amino acids. In the Jisheng San is a drug.
  • Jishengsan Another important ingredient in Jishengsan is pig skin, which is sweet and cool, rich in collagen, followed by elastin, which nourishes yin and raises bloody skin. @@ ⁇ , lowers blood viscosity, resists blood clots, improves microcirculation The role.
  • Pig skin can be replaced by cowhide, suede, or other large mammalian swordsmen.
  • Jisheng San is a drug.
  • Beef tendons can be replaced by beef tendons, or other large mammals with tendons (legs) or tendons.
  • Jisheng San is an adjuvant.
  • the jujube meat in Jishengsan is sweet, flat, non-toxic, beneficial to the spleen and stomach, and it is used as a flavoring agent.
  • Jisheng San for the medicine.
  • the beef, beef tendon and pig skin in Jisheng San are all flesh and blood, have a strong qi and nourishing effect, improve the body's copper dog condition, anti-aging, and significantly enhance human immunity. effect.
  • Jisheng is in the treatment of the standard, and the active ingredient of the drug is animal protein hydrolysate, which is composed of a variety of amino acids as the main component.
  • the pharmacological action of the nutrient is the body's synthesis of HDL. It has a variety of amino acids that are highly efficient and sufficient to provide the ideal HDL levels for human synthesis. It is a substance that raises the serum HDL concentration.
  • the preparation method of Jishengsan is to use the earning hydrolysis process. Add the appropriate amount of water to the container and add the Artin Hydrolase. The reaction is carried out to prepare animal protein hydrolysate.
  • the combination of the middle-adjusting tablets and the Jishengsan of the present invention can cooperate with each other, complement each other, and synergistically play a role of significantly increasing the serum HDL concentration, and is suitable for the prevention of heart and cerebrovascular diseases caused by atherosclerosis. Treatment; can also be used for anti-aging.
  • the spleen and stomach are the hubs of the body's qi and qi.
  • the spleen is promoted by the spleen (liver, kidney, trifocal, small intestine, large intestine), and the stomach is descended (pulmonary, heart, pericardium, gallbladder).
  • the bladder can be lowered; the human body can reach the realm of no stagnation of the meridians and qi and blood, and the nutrients in the body can be fully digested, absorbed, transported, metabolized, secreted and excreted. This is the physiological basis for the human body to synthesize the ideal HDL 7 flat.
  • the medium-adjusting tablet of the invention focuses on conditioning the spleen and stomach, recovering the cardinal of normal lifting, thereby making the body's internal gas rise and fall normally and orderly; improving the internal environment of the human body to achieve an ideal state of balance, neutrality and harmony.
  • the nutrients such as amino acids necessary for listening to the ideal LDL level of 1J human body can be fully digested, absorbed and efficiently reported. Therefore, the medium is adjusted to increase the serum HDL concentration of the base drug.
  • Nutritional immunology also tells us that human beings have an awesome, sophisticated and complex system. Only the system is healthy and powerful. Cancer can recover quickly like a cold. In addition to hereditary diseases, almost human diseases. Both are related to the immune response. Enhancing human immunity and keeping it functioning properly, most human diseases are expected to be cured. The only way for people to do everything is to provide adequate nutrition to the immune system, restore it and stay healthy and strong, and recover even if it is sick. This is the secret of health and longevity. This theory is consistent with the academic thought of the Yellow Emperor's internal classics, "Positive in the air, evil can not be done.”
  • the traditional Chinese medicine compounding group of the invention is composed of two parts: “Tune in the middle” and “Jishengsan”.
  • Preparation method The four-flavored medicine of the middle-adjusting tablet is uniformly mixed and rinsed with water, and then 1/10 of the total weight is weighed out for drying and pulverization to prepare a dry powder for use; and then processed according to the traditional Chinese medicine pharmaceutical process; The process: soaking the remaining drugs ⁇ decoction ⁇ filtration ⁇ «
  • Preparation method of Jishengsan mmtm, ? rinse; beef, beef tendon, pig skin should be cut into small pieces or strips; then cook them 10 H ⁇ i5 j finely, add water to make a suitable paste; Then it is processed by the Lancui hydrolysis process.
  • paste drug add papaya protein hydrolysis at 60 ° C for 12 hours for hydrolysis reaction ⁇ boil 15 off! ⁇ High-speed centrifugal degreasing, desiccation ⁇ filtration ⁇ liquid animal protein hydrolysate ⁇ concentration ⁇ spray drying ⁇ package ⁇ ⁇ Powdered finished product. Cong 10 ⁇ 15 grams.
  • the tablets, powders, and pellets obtained from the three examples of the middle sheet can be combined with the powdered products obtained from the three examples of Jishengsan.
  • the traditional Chinese medicine compound group _Tiaozhong tablets and Jishengsan can significantly increase the serum HDL concentration, and the effect is superior to the western medicine niacin and statins, and is a traditional Chinese medicine which advocates the potential of great value in nature.
  • the Jisheng Powder of the present invention is rich in a variety of amino acids, and is a main substance constituting various immune cells, antibodies, complements and the like of the human body. Only in the case of a wide variety of amino acids and a sufficient number of cattle, the human body can normally synthesize various immune cells, antibodies, complements, etc., wherein the present invention significantly enhances the body's immunity and keeps the immune system healthy and powerful. The vast majority of diseases, including serum HDL 7 levels, are expected to be cured.
  • the serum HDL concentration value of the subject at the beginning is the baseline, and the serum HDL concentration value of the subject is the largest in the first to sixth years after administration.
  • the increase was 92.6%, and the minimum increase was 43.9%.
  • the median serum HDL concentration in 6 years was 65.6% higher than the baseline; no obvious side effects, liver and kidney function were observed. No abnormalities have been observed.
  • This experiment confirmed that the present invention can greatly increase serum HDL concentration, and its effect is superior to western medicine niacin and statins.
  • the present invention can significantly increase the serum HDL concentration, and has no obvious toxic and side effects, and can be cut for a long time; although the effect is slow (at least 3 months), the effect is stable and long-lasting after the effect; and can be combined with statins.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)

Abstract

提供了一种显著升高血清高密度脂蛋白浓度的中药组合物,它由北山楂30%-50%、木香10%-30%、北沙参10%-30%和川芎10%-30%制成的片剂以及由牛肉40%-60%、牛筋腱15%-35%、猪肤15%-35%和大枣0.5-2.5%制成的散剂组成,其中所述片剂通过用水煎煮所述原料药制备,所述散剂通过用酶催化水解制备,所述散剂中的猪肤可以用牛皮或驴皮替代,所述牛筋腱可以用牛蹄筋替代。

Description

说 明 书
显著升高血清高密度脂蛋白浓度的中药复 且^/和制备方法 本发明涉及动脉粥样硬化弓 1起的心脏和脑血管疾病的预防和治疗领域, 具術歩及一 种显著升高血清高密度脂蛋白 (HD 浓度的中药复合组方。
背景
高密度脂蛋白 (high density lipoprotein; HDL)主要由肝和小肠合成, 粒最 小的血清脂蛋白。 1975年,美国的 Miller博士首先发现了抗动脉粥样硬化因子 HDL, 由 此揭示冠心病并不都是由高血脂弓 1发, HDL水平的降低也可能是冠心病的一个重要的甚 至是关键性的发病原因。
1985年, 美国的布朗和古斯坦因博士以全新的角度阐述了 HDL的代谢机理: HDL 育 多驱动胆固醇逆转运, » 转运作用把血液和组织中多余的胆固醇等 "血液垃圾" 携带经肝脏分解逆向排除体外, 同时 HDL具有逆转内皮功能不良、 减少血小板聚集、 抑 制 LDL (低密度脂蛋白)氧化等许多功能。 由于这两位博士的突出贡献, 被授予诺贝尔 医学大奖。
近来科学研究已证明, HDL具有明确的抗动脉粥样硬化的作用,可以将动脉粥样硬化 血管壁内的胆固醇"吸出", 并运输到肝脏进行代 i静凊除。 动脉造影也证实 HDL含量与 动脉管腔狭窄程度呈显著的负相关, 因此 HDL具有"血管清道夫"的美称。 国际医学界 清楚地认识 J ~ "谁能大幅度升高 HDL, 谁就解决了冠心病甚至是針心脑血管疾病的 问题, 谁就能把人类的絲从理论上延长几十年。
2006年, 中国、美国、英国等五个国家和地区的多个医学中心共同参与, 口服烟酸 和辛伐他汀升高血清 HDL、 降低 LDL的研究, 历时 4年, 共观察了 3万多例冠心病人。 在这项大样本、 随机、 双盲、 安慰剂对照的研究中, 通大量循证医学证据证实: 口服 烟酸和辛伐他汀升高血清 HDL的效果并不理想。 目前, 国际上还没有一种升高血清 HDL 的理想药物。 因此依托中医药这座伟大的宝库, 发挥中医药治疗各种慢性疾病的优势, 发掘 发出一种显著升高血清 HDL的中药复合组方和制备方法是非常必要的。
发明内容
本发明的目的是提供一种显著升高血清 HDL的中药复合组方,弥补现有技术的不足, 以改变目前临床上没有一种理想的升高血清 HDL的中医药物可用的现状。
本发明的中药复合组方由以下 "调中片"和 "济生散"两方组合而成。
1. 调中片
本发明的调中片是由以下药物组成: 北山楂、木香、北沙参、川芎, 其中各组分 的重量百分比分别为: 北山楂 30Q/M0%, 木香 10%— 30%, 北沙参 10¾^_30%, 川芎 10% —30%。 本发明的调中片各组分的靈百分比还可以为:北山楂 35¾τ"45%,木香 15%— 25%, 北沙参 15%— 25%, j 11芎 15%—25%
或者调中片各组分的重量百分比为:北山楂 40%,木香 20%,北沙参 18%,川芎 22% 其中调中片中主要成分是木香, 药 辛、 苦、 温, 有调中导滞, 健脾消食, 行气 iM的作用。 在调中片中为君药。
调中片中另一种重要成分是北山楂, 药 酸、甘、微温, 有消食化积, 活血化瘀的 作用。研究显示, 北山楂可降低血脂、改善血液循环、阻止麪离子传递、协助稳定心肌, 抗高血压、 抗动脉粥样硬化的作用。 在调中片中为臣药。
调中片中的川芎, 药 辛、 温, 有活血行气, 祛风 iM的作用。
调中片中的北沙参, 药 甘、騰, 有益胃生津、清肺养阴的作用。川芎、北沙参 在调中片中均为佐药。
本发明的调中片中四味药物配伍后, 具有调养中气、健脾开胃, 纠正中虚胃弱,恢 复脾胃正常生理功能; 还兼有滋阴、 活血化瘀的作用。 本方重在治本, 先从调理脾胃功 能入手, 将人体合成 LDL所必需的氨基酸 勿质的消化、 吸收和转化过程中存在的障碍 作为治疗目标, 首先恢复人体内环境合成理想的 HDL 7JC平的生理基础, 为济生散的应用 及其药效的充分发挥创造了餅, 这是显著升高血清 HDL浓度的关键。
调中片的制备方法采用传统中药制药工艺法。 7煎、 m,制成片剂; 也可制成散 齐 1」、 丸剂、 胶囊剂。
2. 济生散
本发明的济生散是由以下药物组成: 牛肉、牛筋腱、猪肤、大枣肉, 其中各组分的 重量百分比分别为:牛肉 40¾^"60%,牛筋腱 15°/(τ-35%,猪肤 15°/(τ-35%,大枣肉 0. 5%— 2. 5% 本发明的济生散各组分的靈百分比还可以为:牛肉 45°/Μ5%,牛筋腱 20%— 30% 猪肤 20%—30%, 大枣肉 I0/ 2%
或者济生散各组分的重量百分比为: 牛肉 50%, 牛筋腱 24%, 猪肤 25%, 大枣肉
1%
其中济生散中主要成分是牛肉, 药 甘、 温、 无毒, 有安中益气、 养脾胃的作用。 富含牛肉蛋白质, 是获取氨基酸的主要来源。 在济生散中为君药。
济生散中另一种重要成分是猪肤, 药 甘、 凉, 富含胶原蛋白, 其次为弹性蛋白, 有滋阴、 提高血顏 «@压、 降低血粘度、 抗血凝、 改善微循环的作用。
猪肤可用牛皮、 驴皮代替, 或其他大型哺乳动物的劍夫代替。 在济生散中为臣药。
济生散中的牛筋腱(腿大筋), 药 、凉, 富含硬蛋白, 其中主要有角蛋白、胶 原蛋白、 网硬蛋白和弹性蛋白等, 对维 ¾力脉的弹性和健康有关。 牛筋腱可用牛蹄筋代 替, 或其他大型哺乳动物的筋腱(腿大筋)或蹄筋代替。 在济生散中为佐药。
济生散中的大枣肉, 甘、 平、 无毒, 有益脾平胃生津的作用, 方中用它作矫味剂。 在济生散中为使药。
济生散中的牛肉、牛筋腱、猪肤均为血肉有情之品, 有很强的补气滋阴作用, 具有 改善人体的营銅犬况、 抗衰老、 还有显著增强人体免疫力的作用。 济生 在治标, 其 含有的药物有效成分是动物蛋白质水解物, 是一种由多种氨基酸为主要成分组成的具有 药理作用的营养剂, 是机体合成 HDL的必爾勿质。 它具有高效、 足量提供人体合成理想 的 HDL水平所需要的多种氨基酸, 它 著升高血清 HDL浓度所 |«的物质。
济生散制备方法是采用赚化水解工艺法。 药物置容器内加适量水, 再加 Art蛋 白水解酶。 解反应制取动物蛋白质水解物。
本发明的调中片和济生散组合在一起应用, 可互相配合、 相辅相成、 协同发挥显著 升高血清 HDL浓度的作用,适宜于动脉粥样硬化弓 1起的心脏和脑血管疾病的预防和治疗; 也可用于抗衰老。
本发明研发的理论依据:
2000多年前的黄帝内经已载明: "病非人体素有之物, 能得也能除。言不可治者, 未得其术也。 "遵循古训, 发挥中医药治疗各种慢性疾病的优势, 发掘并研发出一种显 著升高血清 HDL浓度的中药复合组方 _调中片和济生散, 以解决血清 HDL 7平降低这 一医学难题。
根据经典中医学的理论, 脾胃是全身诸经气升降的枢纽, 脾经升诸经(肝、 肾、三 焦、 小肠、 大肠经) 皆升, 胃经降诸经(肺、 心、 心包、 胆、 膀胱经) 皆降; 人体才 能达到经脉无滞、 气血平和的境界, ί Λ体内的营养物质才能充分地消化、 吸收、 输 佈、 代谢、 分泌、 排泄。 这是人体合成理想 HDL 7平的生理基础。
本发明的调中片重在调理脾胃二经,恢复其正常升降的枢机,从而使全身诸经气升 降正常、 有序; 改善人体的内环境, 使之达到平衡、 中正、 和谐的理想状态。 以聽 1J人 体合成理想的 LDL水平所必需的氨基酸等营养物质能够充分消化、 吸收及高效報化。 因此调中片 ¾ 著升高血清 HDL浓度的基础药物。
营养免疫学也告诉我们,人类有一套令人敬畏的、精密复杂的免 统,只有该系 统健康、 强大, 癌症也会像感冒一样很快康复, 除了遗传性疾病之外, 几乎人 有 的疾病都与免疫反应有关。 提升人体免疫力并使之保持正常运作, 人类绝大部分疾病 都有望治愈。 人们千方百计、 惟一能做到的是给免疫系统提供充足的营养, 使之恢复 并保持健康、 强大, 即使生了病也能痊愈, 这也是健康、 长寿的秘诀。 该理论与黄帝 内经的 "正气存内, 邪不可干" 的学术思想一致。
具体鎌方式
下文结合具体实施例详述本发明。
本发明的中药复合组方由 "调中片"和 "济生散"两方组合而成。
一.调中片
錢例 1:
称取北山楂 5公斤、 木香 1. 8公斤、 北沙参 1. 6公斤、 川芎 1. 6公斤, 待用。
制备方法: 将调中片的四味药物经 、混合均匀后水冲洗,再从其中称取总重的 1/10 预先进行供干、 粉碎制成干粉备用; 然后按照传统中药制药工艺法加工; 其工艺流程: 将余下的药物浸泡→水煎→过滤→«|→加入±¾全部干粉→初歩形成固体药物→烘 干→粉碎制粉→制成片剂。 每片 0. 3克"^ 4克。
月艮用方法: 口服; 成人每次 4 片, 每日二次。 通常也可制成散剂、 丸剂、 胶囊剂。
雄例 2:
称取北山楂 3. 5公斤、 木香 2. 5、 北沙参 1. 6公斤、 川芎 2. 4公斤, 待用。
制备方法和服用方法与实施例 1相同。
錢例 3:
称取北山楂 4公斤、 木香 2公斤、 北沙参 1. 8公斤、 川芎 2. 2公斤, 待用。
制备方法和服用方法与实施例 1相同。
二济生散
鎌例 1:
称取牛肉 6公斤、 牛筋腱 1. 5公斤、 猪肤 2. 3公斤、 大枣肉 0. 2公斤, 待用。
济生散的制备方法: mmtm, ?冲洗; 牛肉、牛筋腱、猪肤需切细成小块或小条; 再将它们煮 10 H^i5 j 磨细、 加水调成适当的糊剂; 然后采用蘭崔化水解工艺 法加工。其工艺流程: 糊剂药物→加木瓜蛋白水解 在摄氏 60度保温 12小时进行水 解反应→煮沸 15 灭! ^高速离心脱脂、 去澄→过滤→液状动物蛋白质水解物→浓 缩→喷雾干燥→包^→粉状成品。 聰 10~15克。
服用方法: 开水冲调口服; 成人每次一包, 每日三次, 可以随餐服用。 鎌例 2:
称取牛肉 4. 5公斤、 牛筋腱 2. 35公斤、 猪肤 3公斤、 大枣肉 0. 15公斤, 待用。
制备方法和服用方法与实施例 1相同。
鎌例 3:
称取牛肉 5公斤、 牛筋腱 2. 4公斤、 猪肤 2. 5公斤、 大枣肉 0. 1公斤, 待用。
制备方法和服用方法与实施例 1相同。
棚时, 调中片的三个实施例得到的片剂、 散剂、 丸布 l交囊剂, 可与济生散的三个 实施例得到的粉状成品任意组合搭配棚。
本发明的中药复合组方 _调中片和济生散可显著升高血清 HDL浓度, 其效果优于西 药烟酸、 他汀类, 是一种崇尚自然具有潜在巨大价值的祖国中医药物。
: m实用性
本发明的济生散富含多种氨基酸,它是构成人体的各种免疫细胞、抗体、补体等的 主要物质。 只有在氨基酸的种类丰富和数量充足的 牛下, 人体才能正常合成各种免疫 细胞、 抗体、 补体等, 其中本发明的济生散显著增强了人体免疫力, 使免疫系统保持健 康、强大, 人类绝大部分疾病,包括血清 HDL 7平降低才能有望治愈。另外, 根据生物 化学的原理, 人体利用氨基酸等物质合成 HDL的謝足反应中, 在酶浓度和其他条件不变 的清况下,增加底 / ~ "氨基酸的浓度能增加 HDL的合成速度;在氨基酸充足的 牛下, 生成的产^ ~ HDL增多, 就能升高血清 HDL浓度。 济生散能够高效、 足量提供人体合 HDL所需要的多种氨基酸, 是显著升高血清 HDL浓度所 的物质。 显然本发明的调中片和济生散组合在一起应用, 本标兼治、 协同作用, 充分发挥显 著升高血清 HDL浓度的功效。
在一小样本、历时 6年应用本发明升高血清 HDL浓度的实验中,以开始时受试者血 清 HDL浓度值为基线, 用药后第 1至第 6年受试者血清 HDL浓度值的最大升高幅度为 92. 6%, 最小升高幅度为 43. 9%, 6年血清 HDL浓度值的中位数比基线升高了 65. 6%; 未 见明显的毒副作用, 肝、 肾功也未见异常。 该实验证实本发明可大幅度升高血清 HDL浓 度, 其效果优于西药烟酸、 他汀类。
显然, 本发明可显著升高血清 HDL浓度, 而且无明显的毒副作用, 并可长期月削; 虽然 起效缓慢(至少需要 3个月时间) , 但显效后效果稳定、 持久; 且可与他汀类药物耳給 应用, 治养结合, 寓治于养, 应用方便。 是一种崇尚自然具有潜在巨大价值、 有望成为

Claims

权 利 要 求 书
1、 一种显著升高血清高密度脂蛋白浓度的中药复合组合物, 其特征在 于该组合物由调中片和济生散两方组合而成, 其中调中片是由以下药物组 成: 北山楂、 木香、 北沙参、 川芎, 其中各组分的重量百分比分别为: 北 山楂 30%— 50%, 木香 10%— 30%, 北沙参 10%— 30%, 川芎 10%— 30% ;
济生散是由以下药物组成: 牛肉、 牛筋腱、 猪肤、 大枣肉, 其中各组分 的重量百分比分别为: 牛肉 40%— 60%, 牛筋腱 15%— 35% , 猪肤 15%— 35%, 大枣肉 0. 5%— 2. 5% ;
调中片的制备方法: 将调中片的四位药物经挑选、 混合均匀后水冲 洗, 再从其中称取总重的 1/10预先进行烘干、 粉碎制成干粉备用; 然后按 照传统中药制药工艺法加工; 其工艺流程: 将余下的药物浸泡→水煎→过 滤→浓缩→加入上述全部干粉→ 初歩形成固体药物→烘干→粉碎制粉→ 制成片剂;
济生散的制备方法: 药物经挑选、 水冲洗; 牛肉、 牛筋腱、 猪肤需 切细成小块或小条; 再将它们煮 10分钟一 15分钟, 磨细、 加水调成适当 的糊剂; 然后采用酶催化水解工艺法加工; 其工艺流程: 糊剂药物→加木 瓜蛋白水解酶→在摄氏 60度保温 12小时进行水解反应→煮沸 15分钟灭酶 →高速离心脱脂、 去渣→过滤→液状动物蛋白质水解物→浓缩→喷雾干燥 →包装→粉状成品。
2、如权利要求 1所述的中药复合组合物, 其特征在于上述组合物的调 中片各组分的重量百分比为: 北山楂 35%— 45%, 木香 15%— 25%, 北沙参 15%— 25% , 川芎 15%— 25% ;
济生散各组分的重量百分比为: 牛肉 45%— 55%, 牛筋腱 20%— 30%, 猪 肤 20%— 30%, 大枣肉 1%— 2% 。
3、 如权利要求 1所述的中药复合组合物, 其特征在于该组合物的调 中片各组分的重量百分比为:北山楂 40%,木香 20%,北沙参 18%,川芎 22%; 济生散各组分的重量百分比为: 牛肉 50%, 牛筋腱 24%, 猪肤 25%, 大枣肉 1% 。
4、 如权利要求 1所述的中药复合组合物, 其特征在于济生散中的猪 肤用牛皮或驴皮代替。
5、 如权利要求 1所述的中药复合组合物, 其特征在于济生散中的牛 筋腱用牛蹄筋代替。
PCT/CN2014/079771 2013-08-30 2014-06-12 显著升高血清高密度脂蛋白浓度的中药复合组合物和制备方法 WO2015027730A1 (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2016537097A JP6273017B2 (ja) 2013-08-30 2014-06-12 血清高密度リポタンパク質(hdl)濃度を著しく増加させる漢方薬複合組成物及び製造方法
US14/771,505 US9861664B2 (en) 2013-08-30 2014-06-12 Traditional chinese medicine complex composite for significantly improving high density lipoprotein concentration in serum and preparation method thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201310384204.5 2013-08-30
CN201310384204.5A CN103405538B (zh) 2013-08-30 2013-08-30 显著升高血清高密度脂蛋白浓度的中药复合组合物和制备方法

Publications (1)

Publication Number Publication Date
WO2015027730A1 true WO2015027730A1 (zh) 2015-03-05

Family

ID=49598612

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2014/079771 WO2015027730A1 (zh) 2013-08-30 2014-06-12 显著升高血清高密度脂蛋白浓度的中药复合组合物和制备方法

Country Status (4)

Country Link
US (1) US9861664B2 (zh)
JP (1) JP6273017B2 (zh)
CN (1) CN103405538B (zh)
WO (1) WO2015027730A1 (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103405538B (zh) * 2013-08-30 2014-07-23 高庄存 显著升高血清高密度脂蛋白浓度的中药复合组合物和制备方法
CN105079774A (zh) * 2015-09-18 2015-11-25 高庄存 一种升高hdl的组合物及其应用
US11448013B2 (en) 2018-12-05 2022-09-20 Epiroc Drilling Solutions, Llc Method and apparatus for percussion drilling
CN111184221B (zh) * 2019-10-21 2023-06-27 青海宏健生物科技集团有限公司 一种牦牛蹄筋胶原蛋白口服液及其制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101069731A (zh) * 2007-05-11 2007-11-14 赵震峰 治疗高血压的中成药胶丸及制备方法
CN102940255A (zh) * 2012-11-29 2013-02-27 蒋科富 一种牛肉肠
CN103405538A (zh) * 2013-08-30 2013-11-27 高庄存 显著升高血清高密度脂蛋白浓度的中药复合组方和制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1320916C (zh) * 2005-04-15 2007-06-13 吴金珠 治疗高血脂症的降脂通脉中药
US20070059386A1 (en) * 2005-09-12 2007-03-15 Tsun-Nin Lee Modular system for novel Chinese herbal formulas
CN100522197C (zh) * 2006-06-23 2009-08-05 陕西香菊药业集团有限公司 治疗高脂血症的中药制剂及其制备方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101069731A (zh) * 2007-05-11 2007-11-14 赵震峰 治疗高血压的中成药胶丸及制备方法
CN102940255A (zh) * 2012-11-29 2013-02-27 蒋科富 一种牛肉肠
CN103405538A (zh) * 2013-08-30 2013-11-27 高庄存 显著升高血清高密度脂蛋白浓度的中药复合组方和制备方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HU , YONGHE: "Recent Development for Treatment of Diabetes and Hyperlipemia by Chinese s Medicine", JETCM, vol. 14, 31 July 2005 (2005-07-31) *

Also Published As

Publication number Publication date
US9861664B2 (en) 2018-01-09
CN103405538B (zh) 2014-07-23
US20160008406A1 (en) 2016-01-14
JP6273017B2 (ja) 2018-01-31
JP2016529261A (ja) 2016-09-23
CN103405538A (zh) 2013-11-27

Similar Documents

Publication Publication Date Title
EP3530277A1 (en) Chinese medicine healthcare preparations for slimming and weight loss
CN105727081A (zh) 一种用于治疗痛风的保健品组合物
CN105126067A (zh) 一种降尿酸的组合物及其用途
WO2010054520A1 (zh) 净化血管的药物组合物及其制备方法
WO2015027730A1 (zh) 显著升高血清高密度脂蛋白浓度的中药复合组合物和制备方法
CN104432050A (zh) 一种猴头菇营养羹及其制备方法
CN104473169B (zh) 一种含鱼胶的保健品及其制备方法
CN106418132A (zh) 一种山药降血脂粉及其制备方法
CN103893613A (zh) 一种治疗口腔溃疡的药物及制备方法
CN103494198A (zh) 解酒汤料的配方及其生产方法
CN113925172A (zh) 一种适用于儿童的大鲵肽营养组合物
CN105688110A (zh) 一种阿胶补血养颜口服液及其生产方法
CN104800600A (zh) 一种治疗高血压的药物
CN104013853B (zh) 一种健肾补肾的组合物及其制备方法
CN103932001B (zh) 一种具有减肥、调节血脂的保健食品及其制备方法
CN114632098B (zh) 一种利用鸡血藤制备黄酮精制物的方法
CN106551312A (zh) 一种中老年益寿糕
CN105168369A (zh) 一种螺旋藻强体抗衰老酒及其制备方法
CN105687985A (zh) 一种补骨脂暖脾止泻口服液及其生产方法
CN102824572B (zh) 排毒保健的中药及其制备方法
CN105687808A (zh) 一种白及收敛止血口服液及其生产方法
CN104522573A (zh) 一种和胃降逆的葛根粉
CN103783479A (zh) 黑虎掌菌补脑健脑火锅调料及其生产方法
CN103829197A (zh) 一种党参益气生津火锅料及生产方法
CN104069371A (zh) 一种辅助治疗月经不调的保健泡腾片及其制备方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14839226

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 14771505

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2016537097

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14839226

Country of ref document: EP

Kind code of ref document: A1